GlassScriptPhysician profile
Martha J Todd
NPI 1407800139
$8,987.05
in general payments reported to CMS, 2019-2025
43 companies · $2,106 in 2025
The $2,106 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,587 · 2022: $1,879 · 2023: $1,887 · 2024: $1,528 · 2025: $2,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,436 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,436.07 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,071.36 | 2021-2025 | |
| Novo Nordisk INC | $810.81 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $772.08 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $657.14 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $648.38 | 2021-2025 | Evenity, Otezla, Repatha |
| Glaxosmithkline, LLC. | $489.60 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Otsuka America Pharmaceutical, INC. | $427.00 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $404.76 | 2021-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $404.07 | 2021-2025 | Xifaxan |
| Astellas Pharma US INC | $388.78 | 2021-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $336.05 | 2021-2025 | |
| Dexcom, INC. | $264.87 | 2022-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.73 | 2023-2024 | Jardiance |
| Lundbeck LLC | $235.22 | 2023-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $205.39 | 2023-2025 | Keveyis, Gvoke Hypopen |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.